Nanoengineered immune check point inhibitors delivery for targeted brain cancer treatment: Current status and future...

Area of Science:

• Neuro-oncology
• Nanotechnology
• Immunotherapy

Background:

• Brain tumors present unique treatment challenges due to the blood-brain barrier (BBB) and a suppressive tumor microenvironment.
• Conventional therapies like surgery and chemotherapy have limited efficacy against aggressive brain cancers.
• Immune checkpoint inhibitors (ICIs) show therapeutic potential but face delivery and efficacy hurdles in brain cancer.

Purpose of the Study:

• To explore nanoengineering strategies for improving the delivery and efficacy of ICIs in brain tumors.
• To address the challenges posed by the BBB and the tumor microenvironment to ICI therapy.
• To review current advancements and future directions in nanotechnology-based ICI treatments for brain cancer.

Main Methods:

• Utilizing nano-delivery systems (liposomes, micelles) to facilitate BBB crossing via transcytosis and the EPR mechanism.
• Functionalizing nanocarriers for enhanced tumor cell targeting and treatment precision.
• Co-delivering ICIs with adjuvants and targeting immune cells (TAMs, Tregs) to modulate the tumor microenvironment (TME).

Main Results:

• Nanoengineered ICIs demonstrated significant improvements in efficacy and reduced toxicity in preclinical animal models.
• Functionalized nanocarriers enhance targeting, improving treatment accuracy.
• Combinatorial approaches with adjuvants and immune cell modulation show potential for boosting anti-tumor immunity.

Conclusions:

• Nanoengineered ICIs offer a promising strategy to overcome current therapeutic limitations in brain cancer.
• Clinical translation faces regulatory and safety challenges, including scalability and long-term safety.
• Future research integrating personalized medicine, nanotechnology, and AI holds potential for refined brain cancer treatments.